Business Wire

New Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that provide important insights into the mechanisms of TEPEZZA™ (teprotumumab-trbw), illustrating its ...
Fierce Pharma

Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa

Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...
The Globe and Mail

Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next

This Phase 3b/4 post‑marketing study, officially titled “A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate ...
pharmaphorum

FDA clears Viridian's Tepezza rival for thyroid eye disease

Viridian Therapeutics has fired a shot across Amgen's bows with FDA approval of Lumvoa, the first direct rival to Amgen's ...
Yahoo

Viridian's drug cuts thyroid eye disease symptoms in late-stage study

(Reuters) -Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the ...
Nasdaq

New Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy

-- Additional Horizon data accepted as a poster presentation at ENDO 2020 summarize the first U.S.-based assessment of the GO-QOL questionnaire and demonstrate the significant burden of Thyroid Eye ...